Literature DB >> 25395432

Contrasting Cholesterol Management Guidelines for Adults with CKD.

Lisandro D Colantonio1, Usman Baber2, Maciej Banach3, Rikki M Tanner1, David G Warnock4, Orlando M Gutiérrez5, Monika M Safford4, Christoph Wanner6, George Howard7, Paul Muntner8.   

Abstract

The Kidney Disease Improving Global Outcomes Lipid Work Group recommends statins for adults ≥50 years old with CKD. The American College of Cardiology/American Heart Association endorses statins for adults with atherosclerotic cardiovascular disease, adults with LDL cholesterol≥190 mg/dl, and adults 40-79 years old with LDL cholesterol=70-189 mg/dl and diabetes or a 10-year predicted risk for atherosclerotic cardiovascular disease ≥7.5% estimated using the Pooled Cohort risk equations. Using data from the Reasons for Geographic and Racial Differences in Stroke Study, we calculated the agreement for statin treatment between these two guidelines for adults 50-79 years old with CKD (eGFR<60 ml/min per 1.73 m(2) or albuminuria≥30 mg/g) not on dialysis. We assessed the validity of the Pooled Cohort risk equations in individuals with CKD. Study participants were enrolled between 2003 and 2007, and we report incident cardiovascular disease events (stroke and coronary heart disease) through December of 2010. Among 4726 participants with CKD, 2366 (50%) were taking statins, and 1984 (42%) were recommended statins by the American College of Cardiology/American Heart Association guideline but not taking them. Overall, 376 (8%) participants did not meet the American College of Cardiology/American Heart Association criteria for initiating statin treatment. Cardiovascular disease incidence was low (3.0/1000 person-years; 95% confidence interval, 0.1 to 5.9) among these participants. The Pooled Cohort risk equations were well calibrated (Hosmer-Lemeshow chi-squared=2.7, P=0.45) with moderately good discrimination (C index, 0.71; 95% confidence interval, 0.65 to 0.77). In conclusion, these guidelines show high concordance for statin treatment for adults with CKD.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  cardiovascular disease; cholesterol; chronic kidney; disease; practice guidelines; statins

Mesh:

Substances:

Year:  2014        PMID: 25395432      PMCID: PMC4413767          DOI: 10.1681/ASN.2014040400

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  39 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.

Authors:  Hans L Hillege; Vaclav Fidler; Gilles F H Diercks; Wiek H van Gilst; Dick de Zeeuw; Dirk J van Veldhuisen; Rijk O B Gans; Wilbert M T Janssen; Diederick E Grobbee; Paul E de Jong
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690

3.  Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation.

Authors:  Michael J Pencina; Ralph B D'Agostino
Journal:  Stat Med       Date:  2004-07-15       Impact factor: 2.373

4.  Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute.

Authors:  Russell V Luepker; Fred S Apple; Robert H Christenson; Richard S Crow; Stephen P Fortmann; David Goff; Robert J Goldberg; Mary M Hand; Allan S Jaffe; Desmond G Julian; Daniel Levy; Teri Manolio; Shanthi Mendis; George Mensah; Andrzej Pajak; Ronald J Prineas; K Srinath Reddy; Veronique L Roger; Wayne D Rosamond; Eyal Shahar; A Richey Sharrett; Paul Sorlie; Hugh Tunstall-Pedoe
Journal:  Circulation       Date:  2003-11-10       Impact factor: 29.690

Review 5.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

6.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

7.  A review of goodness of fit statistics for use in the development of logistic regression models.

Authors:  S Lemeshow; D W Hosmer
Journal:  Am J Epidemiol       Date:  1982-01       Impact factor: 4.897

8.  Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants.

Authors:  Marcin Barylski; Shekoufeh Nikfar; Dimitri P Mikhailidis; Peter P Toth; Pooneh Salari; Kausik K Ray; Michael J Pencina; Manfredi Rizzo; Jacek Rysz; Mohammad Abdollahi; Stephen J Nicholls; Maciej Banach
Journal:  Pharmacol Res       Date:  2013-03-28       Impact factor: 7.658

9.  Evaluation of the performance and concordance of clinical questionnaires for the diagnosis of heart failure in primary care.

Authors:  Cândida Fonseca; António G Oliveira; Teresa Mota; Fernando Matias; Humberto Morais; Catarina Costa; Fátima Ceia
Journal:  Eur J Heart Fail       Date:  2004-10       Impact factor: 15.534

10.  Stroke--1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders.

Authors: 
Journal:  Stroke       Date:  1989-10       Impact factor: 7.914

View more
  27 in total

1.  We don't prescribe statins to lower cholesterol: we prescribe statins to reduce vascular risk.

Authors:  Marcello Tonelli
Journal:  J Am Soc Nephrol       Date:  2014-11-13       Impact factor: 10.121

Review 2.  Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Authors:  Hemal Bhatt; Monika Safford; Stephen Glasser
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

Review 3.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

Review 4.  Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge.

Authors:  Jacek Rysz; Anna Gluba-Brzózka; Maciej Banach; Andrzej Więcek
Journal:  Int Urol Nephrol       Date:  2015-03-11       Impact factor: 2.370

Review 5.  Using Predicted Cardiovascular Disease Risk in Conjunction With Blood Pressure to Guide Antihypertensive Medication Treatment.

Authors:  Paul Muntner; Paul K Whelton
Journal:  J Am Coll Cardiol       Date:  2017-05-16       Impact factor: 24.094

6.  Chronic kidney disease: Statins in chronic kidney disease: time to move on?

Authors:  Richard Haynes; Christoph Wanner
Journal:  Nat Rev Nephrol       Date:  2015-03-24       Impact factor: 28.314

7.  Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates.

Authors:  Markus P Schneider; Silvia Hübner; Stephanie I Titze; Matthias Schmid; Jennifer Nadal; Georg Schlieper; Martin Busch; Seema Baid-Agrawal; Vera Krane; Christoph Wanner; Florian Kronenberg; Kai-Uwe Eckardt
Journal:  Kidney Int       Date:  2015-09-02       Impact factor: 10.612

Review 8.  Recent Update to the US Cholesterol Treatment Guidelines: A Comparison With International Guidelines.

Authors:  Matthew Nayor; Ramachandran S Vasan
Journal:  Circulation       Date:  2016-05-03       Impact factor: 29.690

Review 9.  Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.

Authors:  Roy O Mathew; Robert S Rosenson; Radmila Lyubarova; Rafia Chaudhry; Salvatore P Costa; Sripal Bangalore; Mandeep S Sidhu
Journal:  Cardiovasc Drugs Ther       Date:  2021-06       Impact factor: 3.727

10.  Low statin use in nondialysis-dependent chronic kidney disease in the absence of clinical atherosclerotic cardiovascular disease or diabetes.

Authors:  Talar W Markossian; Holly J Kramer; Nicholas J Burge; Ivan V Pacold; David J Leehey; Zhiping Huo; Julia Schneider; Benjamin Ling; Kevin T Stroupe
Journal:  Clin Kidney J       Date:  2019-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.